Fuso Pharmaceutical Industries,Ltd. AI Stock Analysis
Want to see JP:4538 full AI Analyst Report?
Fuso Pharmaceutical Industries,Ltd. (4538) AI Stock Analysis
Fuso Pharmaceutical Industries,Ltd.
(TSE/TYO:4538)
Fuso Pharmaceutical Industries earns a moderate overall score due to a highly polarized profile. The most significant strengths are its highly attractive valuation metrics and a resilient technical uptrend. However, these upside factors are heavily offset by fundamental risks; despite recovering profitability, the company's severe lack of cash conversion and surging debt load introduce substantial long-term liquidity concerns.
Fuso Pharmaceutical Industries,Ltd. (4538) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 18.73B
- Dividend Yield
- 4.10%
- Average Volume (3M)
- 20.50K
- Price to Earnings (P/E)
- 8.4
- Beta (1Y)
- 0.51
- Revenue Growth
- 2.29%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 1,370
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Fuso Pharmaceutical Industries,Ltd. Business Overview & Revenue Model
Company Description
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artifici...
Fuso Pharmaceutical Industries,Ltd. Financial Statement Overview
Summary
Despite steady revenue growth and a successful return to net profitability, financial health is severely compromised by deep operating cash flow deficits and a rapidly escalating debt burden.
Income Statement
68PositiveBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.85B | 62.31B | 60.56B | 55.41B | 51.02B | 49.63B |
| Gross Profit | 16.11B | 15.99B | 16.19B | 13.52B | 13.36B | 12.91B |
| EBITDA | 5.50B | 5.38B | -2.98B | 3.67B | 4.63B | 4.47B |
| Net Income | 2.19B | 2.01B | -3.29B | 1.38B | 1.60B | 1.48B |
Balance Sheet | ||||||
| Total Assets | 87.47B | 90.32B | 82.52B | 76.46B | 72.81B | 69.66B |
| Cash, Cash Equivalents and Short-Term Investments | 4.57B | 4.85B | 6.26B | 5.12B | 8.01B | 7.35B |
| Total Debt | 26.31B | 28.46B | 21.29B | 12.72B | 11.41B | 12.09B |
| Total Liabilities | 51.72B | 55.26B | 49.48B | 39.79B | 37.15B | 35.12B |
| Stockholders Equity | 35.75B | 35.06B | 33.04B | 36.66B | 35.65B | 34.53B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -7.49B | -5.43B | -2.62B | 1.32B | 2.20B |
| Operating Cash Flow | 0 | -6.22B | -3.31B | 627.00M | 2.87B | 3.61B |
| Investing Cash Flow | 0 | -1.51B | -3.17B | -3.54B | -1.39B | -1.66B |
| Financing Cash Flow | 0 | 6.32B | 7.62B | 14.00M | -813.00M | -1.67B |
Fuso Pharmaceutical Industries,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4538, the sentiment is Positive. The current price of 2194.00 is above the 20-day moving average (MA) of 2123.50, above the 50-day MA of 2157.64, and above the 200-day MA of 2176.09, indicating a bullish trend. The MACD of 6.78 indicates Negative momentum. The RSI at 60.86 is Neutral, neither overbought nor oversold. The STOCH value of 84.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4538.
Fuso Pharmaceutical Industries,Ltd. Peers Comparison
Overall Rating
JP:292971Outperform
JP:457469Neutral
JP:452468Neutral
JP:453866Neutral
JP:453946.5Neutral
JP:451245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | JPY 16.25B | 8.21 | ― | 3.91% | -3.12% | 406.78% | |
| 69Neutral | JPY 12.92B | 30.68 | ― | 1.28% | 13.72% | -50.46% | |
| 68Neutral | JPY 8.98B | 10.28 | ― | 2.95% | -0.47% | 50.82% | |
| 66Neutral | JPY 19.25B | 8.43 | ― | 4.10% | 2.29% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | JPY 5.35B | -11.26 | ― | 3.37% | 0.31% | -194.72% | |
| 45Neutral | JPY 10.07B | 55.88 | ― | 1.21% | 23.41% | 149.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2194.00 | 125.78 | 6.08% | |
| JP:2929 | Pharma Foods International Co., Ltd. | 561.00 | -197.02 | -25.99% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 290.00 | 19.28 | 7.12% | |
| JP:4524 | Morishita Jintan Co., Ltd. | 2202.00 | 111.95 | 5.36% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1483.00 | -14.33 | -0.96% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 258.00 | -36.00 | -12.24% |
Fuso Pharmaceutical Industries,Ltd. Corporate Events
Fuso Pharmaceutical Reports Six-Month Financial Results
Fuso Pharmaceutical Industries Ltd., listed on the Tokyo Stock Exchange, reported non-consolidated results for the six months ended September 30, 2026. Net sales were ¥32,395 million, up 3.7% year on year, while operating profit rose 39.7% to ¥1,743...
Fuso Pharmaceutical FY2026 H1 Results Supplementary Material
Fuso Pharmaceutical Industries, Ltd. provided supplementary material for the six months ended September 30, 2026, covering FY2026 first-half financial highlights and changes in operating profit. It also presents historical and year-on-year net sales...
Fuso Pharmaceutical Announces Executive Officer and Organizational Changes
Fuso Pharmaceutical Industries, Ltd., listed on the Tokyo Stock Exchange Prime Market under securities code 4538, announced changes to its executive officers and organization.Effective January 1, 2027, Satoshi Tanaka will retire as executive officer...
Fuso Pharmaceutical Revises FY2027 Earnings and Dividend Forecasts
Fuso Pharmaceutical Industries, Ltd. has revised its non-consolidated forecasts for the fiscal year ending March 31, 2027. Net sales are now forecast at ¥64.8 billion, operating profit at ¥2.4 billion, ordinary profit at ¥1.8 billion and profit at ¥1...
Fuso Pharmaceutical reports six-month earnings growth
Fuso Pharmaceutical Industries, Ltd., a Tokyo Stock Exchange-listed company, reported non-consolidated financial results for the six months ended September 30, 2026. The release does not specify the company’s industry or primary products and services...
Fuso Pharmaceutical Raises Interim Sales and Profit Forecasts
Fuso Pharmaceutical Industries raised its non-consolidated forecasts for the six months ended September 30, 2026, lifting net sales to ¥32.3 billion, operating profit to ¥1.7 billion, ordinary profit to ¥1.4 billion and profit to ¥1.0 billion. The re...
Fuso Pharma Launches ¥14 Billion Okayama Second Factory to Boost Essential Drug Supply
Fuso Pharmaceutical Industries, Ltd. has signed a design-build contract with Chiyoda X-ONE Engineering Corporation for the construction of the Okayama Second Factory on the existing Okayama site, under its medium-term management plan FUSO VISION 2030...
Fuso Pharmaceutical Delivers Strong Q1 Profits But Keeps Cautious Full-Year Outlook
Fuso Pharmaceutical Industries reported non-consolidated net sales of ¥16.0 billion for the quarter ended June 30, 2026, up 3.5% year on year, with operating profit surging 63% to ¥972 million and profit rising 39% to ¥642 million. Earnings per share...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
